U.S. markets closed
  • S&P 500

    4,232.60
    +30.98 (+0.74%)
     
  • Dow 30

    34,777.76
    +229.23 (+0.66%)
     
  • Nasdaq

    13,752.24
    +119.39 (+0.88%)
     
  • Russell 2000

    2,271.63
    +30.21 (+1.35%)
     
  • Crude Oil

    64.82
    +0.11 (+0.17%)
     
  • Gold

    1,832.00
    +16.30 (+0.90%)
     
  • Silver

    27.57
    +0.09 (+0.32%)
     
  • EUR/USD

    1.2167
    +0.0098 (+0.82%)
     
  • 10-Yr Bond

    1.5770
    +0.0160 (+1.02%)
     
  • GBP/USD

    1.3990
    +0.0098 (+0.70%)
     
  • USD/JPY

    108.5400
    -0.5450 (-0.50%)
     
  • BTC-USD

    59,164.60
    +1,568.02 (+2.72%)
     
  • CMC Crypto 200

    1,480.07
    +44.28 (+3.08%)
     
  • FTSE 100

    7,129.71
    +53.54 (+0.76%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The FDA issued the Emergency Use Authorization (EUA) to Adaptive Biotechnologies Corp's (NASDAQ: ADPT) T-Detect COVID-19 Test on Friday. It will be used to determine whether an individual had been infected with SARS-CoV-2 in the past.

  • This T cell-based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft Corporation (NASDAQ: MSFT).

  • Unlike other tests that detect blood-based antibodies to determine the prior infection with the virus, the T-Detect COVID-19 Test leverages immune repertoire sequencing technology to identify individuals with an adaptive T-cell response to SARS-CoV-2, indicating recent or prior infection.

  • The EUA was issued based on a clinical validation study demonstrating a sensitivity of 97.1% from the date of COVID-19 diagnosis with RT-PCR. The test also showed a specificity of 100%.

  • The FDA noted that the test should not be used to diagnose current SARS-CoV-2 infection.

  • The blood-based test is for use by healthcare professionals on samples from individuals who experienced COVID-19 symptoms at least 15 days earlier, the FDA said. 

  • Price Action: ADPT shares are up 15.7% at $48.84 in the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.